---
title: "A Nine-Month-Old Brain-Interface Startup Raised 464 Million Yuan for Three Product Lines"
date: 2026-11-21
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-active-technology-funding
language: en
---

# A Nine-Month-Old Brain-Interface Startup Raised 464 Million Yuan for Three Product Lines

> Shanghai's Active Technology raised 464 million yuan in an angel-plus round, its second in three months, to push an invasive brain-computer interface toward clinical use.

Most brain-interface startups begin with one ambition: let a paralysed patient move a cursor. This company wants three separate products — one for movement, one for sight, one for mood. The money arrived before any of them had been tested in people.

Shanghai Active Technology (上海主动科技有限公司) announced in early November 2026 that it had completed an angel-plus round of 464 million yuan (≈ US$64.4 million / HK$504 million, approximate). The announcement came through the company's own channel and was reported by Beijing News, Shanghai Securities News and National Business Daily.

It was the second round in three months. In August the company had disclosed a 330 million yuan (≈ US$45.8 million / HK$359 million, approximate) angel round. Cumulative funding now stands at about 800 million yuan (≈ US$111 million / HK$870 million, approximate).

## Who paid, and who is missing

The round was co-led by Gaorong Ventures, SDIC Pioneer and Shanghai Science and Technology Innovation Investment. A long list followed: Kangjun Capital, China Network Investment, Guotai Haitong, Pudong Venture Capital, Shanghai Science and Technology Innovation Fund, Guangyao Capital, Minjin Investment and Yunqi Capital. Earlier investors Daotong Capital, Huada Songhe and InnoCapital added more.

The investor list is dominated by capital with regional and state links. Shanghai-based funds at the municipal, district and park levels appear together. That pattern is becoming common in Chinese brain-computer interface (脑机接口) financing: the money is not purely financial, and it comes with expectations about where clinical work and manufacturing will be located.

Active Technology was founded on February 2, 2026, in the Shanghai Zhangjiang area. Its legal representative is Jia Jing (贾婧).

## Three product lines instead of one

The company describes itself as working on invasive brain-computer interface technology, with in-house capability across flexible electrodes, dedicated chips, decoding algorithms and system integration. Owning the whole chain is unusual for a company this young; most startups specialise in one layer and buy the rest.

On top of that stack sit three product matrices: motion, vision and emotion. The motion line, whose core product is called Tianshu (天枢), is aimed at people with movement and speech difficulties caused by stroke, spinal cord injury or amyotrophic lateral sclerosis. The goal is to rebuild a route for movement and interaction with the outside world.

The vision and emotion lines are less specified in the public material. They draw on the team's earlier research and are described as extensions of the same platform toward different clinical needs.

This breadth is a strategic choice. A single-indication brain-interface company has a narrow path from trial to reimbursement. A platform company can claim a larger addressable market, but it also has to prove three times as much.

## What the 1024-channel report does and does not mean

The most concrete technical claim concerns a 1024-channel invasive brain-computer interface system developed by the core team. In November 2025, that system obtained a type inspection report (型式检验报告).

A type inspection report is a real milestone. It means a device has been tested against a defined standard by a qualified laboratory. It is not a clinical trial, not a marketing approval and not evidence that the device works in patients. Chinese reporting on the round is careful on this point, and the company itself frames the report as a foundation for later clinical research and product translation.

That caution should travel with the headline. A company only months old with four hundred million yuan and a type inspection report is at the engineering stage. The clinical stage is still ahead.

The team behind it includes three doctors: Jia Jing, Zhao Bin (赵斌) and Yi Guoliang (伊国良). Little else is published about their prior work in the reports reviewed.

## Why two rounds in three months

A first financing of 330 million yuan in August and a second of 464 million in November is not a normal sequence for a company with no clinical data. It suggests that early investors were joined by a wider group before the first round's capital had been deployed.

For the company, the advantage is runway. Invasive hardware, regulatory work and laboratory build-out are expensive, and the path to a registrable device is measured in years rather than quarters. Raising twice quickly buys time without waiting for a clinical readout that cannot yet exist.

For the investors, the logic is different. Several of the regional funds are better understood as stakeholders in a future industry cluster than as conventional venture funds seeking a quick exit. They want the clinical resources, suppliers and eventual manufacturing to sit in their jurisdictions.

## Honest limitations

The funding amount, investor names, founding date, product descriptions and type inspection claim come from company announcements reported by Beijing News via Sina, Shanghai Securities News and National Business Daily. I did not find the type inspection report itself or any clinical trial registration for the company's products.

The 800 million yuan cumulative figure is the sum of two rounds of slightly different sizes as reported, and should be treated as approximate. The description of three product matrices is the company's own framing; no clinical evidence for the vision or emotion lines was reported.

The distinction between a type inspection report and regulatory approval is explained above because the coverage is careful about it. Nothing here is medical advice, and patients should not infer that any product is available as a treatment.

## What readers can do now

- **If you follow brain-interface news, learn the vocabulary of approval.** A type inspection report, a registered clinical trial and a device registration certificate are three different things.

- **If you are a patient or carer, ask which stage a device has reached before considering it.** A company only months old with strong funding is still an early-stage company.

- **If you follow the industry, watch where the money comes from.** Regional state capital signals that clinical and manufacturing capacity is being built locally, which shapes where trials will happen.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-active-technology-funding
Free to quote with attribution and a link to the original.
